Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients

This cross-sectional study found that biosimilar competition was associated with lower OOP spending for Medicare patients, likely because many patients paid a percentage of drug costs. These findings suggest that by reducing OOP spending, biosimilar competition can improve access and adherence to biologic medications for Medicare patients.